Three

Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness

TARRYTOWN, N.Y. & MADISON, N.J.--(BUSINESS WIRE)--Jun 28, 2007- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) and WyethPharmaceuticals, a division of Wyeth (NYSE: WYE), today announcedpositive results from a three-month open-label extension study ofsubcutaneous methylnaltrexone for the treatment of opioid-inducedconstipation (OIC) in patients with advanced illness. The resultsare sched...

Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes

- BYETTA also Showed Sustained Improvements in Blood GlucoseControl and Progressive Weight Loss - CHICAGO, June 23, 2007 /PRNewswire-FirstCall/ -- AmylinPharmaceuticals, Inc. and Eli Lilly and Company today announcedresults from a study that showed BYETTA(R) (exenatide) injectionsustained improvements in blood sugar levels and progressive weightloss through three and a half years of thera...

Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis

One Groundbreaking Study Showed 11 Percent Fewer RA PatientsReported Job Loss When Treated With HUMIRA Combination TherapyCompared to Methotrexate Alone BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ --Rheumatoid arthritis (RA) is one of the most common causes ofdisability in the Western world. New data released today show thatrheumatoid arthritis (RA) patients treated with Abbott...

Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment

NEW YORK, June 13, 2007--Three new drugs forrheumatoid arthritis (RA) have ushered in a new era of treatmentfor this difficult and debilitating condition. The findings arereported in a New Drug Class study published early Online and in anupcoming edition of The Lancet. RA is the most common of all chronicinflammatory joint diseases, affecting 0&middo...

ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 24, 2007 - ImmunoGen, Inc.(Nasdaq: IMGN), a biopharmaceutical company that develops targetedanticancer therapeutics using its Tumor-Activated Prodrug (TAP)technology, today announced that clinical findings for threedifferent TAP compounds for the treatment of solid tumors are to bereported at the 43rd American Society of Clinical Oncology (ASCO)Annual...

Separate Sets of Research Show Treatment Improved Quality of Life in as Early as Three Weeks; Patient Adherence to Medication is Multifactorial

WASHINGTON, May 22, 2007 /PRNewswire/ -- Results from analyseslooking at factors contributing to successful treatment ofulcerative colitis (UC), were presented at Digestive Disease Week(DDW) this week. Both of these studies were funded by Procter &Gamble (P&G) Pharmaceuticals, Inc. Findings from one studyoffer new information on improvement of quality of life for UCpatients t...

Isotechnika Announces Interim Three Month Data from Phase 2b Kidney Transplant Trial

EDMONTON, May 07, 2007 /PRNewswire-FirstCall/ - Isotechnika Inc.today announced the audited three month results, reviewed by theData Monitoring Committee, of the first third of the patientstreated in its Phase 2b de novo kidney transplant trial for theCompany's lead immunosuppressive drug, ISA247. This interim analysis is based upon the assessment of the first116 patients enrolled....

Spectrum Pharmaceuticals Announces Data From Three Oncology Programs Presented at the American Association of Cancer Research Annual Meeting

1 EOquin Instillation Immediately Following Transurethral Resectionis Well Tolerated in Phase 2b Bladder Cancer Study IRVINE, Calif., April 19, 2007 /PRNewswire-FirstCall/ --Spectrum Pharmaceuticals, Inc., today announced results of a Phase2b study of EOquin, in non-invasive bladder cancer and thepresentation of preclinical data of SPI (IRL)-1620 and satraplatinat the annual meeting of th...

Data supporting three Antisoma programmes presented at AACR

LONDON, and LOS ANGELES, 16 April 2007- Antisoma announces thatpreclinical data supporting three of its drugs are presented thisweek at the Annual Meeting of the American Association of CancerResearch (AACR). AS1404-Avastin-paclitaxel triple combination highly effectiveAntisoma's scientists have for the first time evaluated a triplecombination of the Company's vascular disrupting a...

EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds

Multiple Mechanisms for Panzem NCD, MKC-1, and ENMD-1198Highlighted at Oncology Drug Discovery Conference ROCKVILLE, Md., March 26, 2007 /PRNewswire-FirstCall/ --EntreMed, Inc., a clinical-stage pharmaceutical company developingtherapeutics for the treatment of cancer and inflammatory diseases,today announced the presentation of comparative mechanism of actiondata for its three lead clini...